Blood or plasma protein concentration stabilizing device for screening coefficient test

Abstract

The utility model provides a blood or plasma protein concentration stabilizing device for a screening coefficient test, and belongs to the technical field of medical instrument detection. The blood or plasma protein concentration stabilizing device for the screening coefficient test comprises a pipeline I, a fibrinolysis mechanism is arranged at the bottom of the pipeline I, the fibrinolysis mechanism is installed in a temperature control fixing mechanism, a blood storage mechanism is further arranged in the temperature control fixing mechanism, and the fibrinolysis mechanism and the blood storage mechanism are communicated through a pipeline IV and a pipeline III. Two ends of the pipeline IV are fixedly connected with the side wall of the pipeline III. In-vitro real-time fibrinolysis can be realized through the fibrinolysis mechanism, the temperature control fixing mechanism, the blood storage mechanism, related pipelines and valves, and fibrous protein solids are prevented from blocking the pipelines, a filter or a concentrator; and the protein concentration in a blood circulation loop necessary for screening coefficient tests of a hemodialyzer, a hemodialysis filter, a blood filter and a blood concentrator is maintained and stabilized at 60g / L + / -5g / L.

Description

Technical Field

[0001] The present application relates to the technical field of medical device detection, and in particular to a blood or plasma protein concentration stabilization device for screening coefficient testing. Background Art

[0002] According to the requirements of YY 0053-2016 "Hemodialyzer, Hemodiafilter, Hemofilter and Hemoconcentrator", the screening coefficient test is a key test method for testing the performance of hemodialyzer, hemodiafilter, hemofilter and hemoconcentrator. This test requires the use of anticoagulated blood or plasma to perfuse the hemodialyzer, hemodiafilter, hemofilter or hemoconcentrator to be tested in advance, relying on pipelines, hemodynamic devices, pressure control devices, and filtrate power devices to form a stable blood circulation circulation loop and simulate blood extracorporeal circulation, so that the protein concentration is stabilized at 60g / L±5g / L. This step is a necessary condition for the screening coefficient test and is also a key link. During the current test, when the stabilizing device is not used, fibrin often precipitates from the blood or plasma to become a solid and no longer enters the circulation loop, which makes the protein concentration in the blood circulation circulation loop often appear below the required range. In severe cases, the fibrin flocs block the pipeline, filter or concentrator, and the test is forced to be interrupted.

[0003] The fibrinolytic reaction requires the use of heparin, and low-molecular-weight heparin sodium is currently commonly used in clinical practice; although in vitro tests do not consider the risk of bleeding from excessive use of low-molecular-weight heparin sodium, studies have shown that excessive low-molecular-weight heparin sodium can cause white blood cell aggregation and thrombocytopenia in the blood, thereby changing the physical and chemical properties of the blood, which is unacceptable for the screening coefficient test. Other studies have pointed out that hemodialyzers and similar blood purification devices will significantly increase the amount of fibrin precipitated as the use time increases, and this cannot be predicted in advance. In summary, the method of adding excess low-molecular-weight heparin to anticoagulated blood or plasma in advance is not applicable. Utility Model Content

[0004] In order to make up for the above deficiencies, the present application provides a blood or plasma protein concentration stabilization device for screening coefficient test to solve the problems raised in the above background technology.

[0005] In order to achieve the above purpose, the technical solution adopted by the utility model to solve its technical problems is:

[0006] A blood or plasma protein concentration stabilization device for screening coefficient test comprises pipeline I, a fibrinolytic mechanism is arranged at the bottom of pipeline I, the fibrinolytic mechanism is installed inside a temperature control fixing mechanism, a blood storage mechanism is also arranged inside the temperature control fixing mechanism, the fibrinolytic mechanism and the blood storage mechanism are connected by pipeline IV and pipeline III, and both ends of pipeline IV are fixedly connected to the side wall of pipeline III.

[0007] Furthermore, a solid separation component is provided inside the fibrinolytic mechanism, and the top of the solid separation component is sealed and connected to the top of the fibrinolytic mechanism in a concentric circle form. The pipeline I and pipeline II are fixedly installed at the sealed connection between the fibrinolytic mechanism and the solid separation component. The bottom end of pipeline I is close to the bottom of the solid separation component, and the bottom end of pipeline II is higher than the bottom end of pipeline I. A deflation valve I is provided on one side of the top of the fibrinolytic mechanism, and an injection port is provided on the other side.

[0008] Furthermore, a circular openable and closable operating window is left in the outer shell of the temperature control fixing mechanism, and a temperature control module and an electric heating module are installed on the inner bottom. A baffle is provided on the top of the temperature control module and the electric heating module. The side wall of the baffle is fixedly connected to the inner wall of the temperature control fixing mechanism, and the surface is fixedly connected to the bottom of the blood storage mechanism.

[0009] Furthermore, a fixture is provided on one side of the inner wall of the blood storage mechanism, and the fixture is fixedly connected to the outer wall of the bottom of the pipeline III. A screw stirring component is installed on the top of the blood storage mechanism, and a power measurement of the screw stirring component is installed on the top. The screw stirring component and the power measurement of the screw stirring component are transmission-connected to each other.

[0010] Furthermore, the blood storage mechanism is provided with inlets and outlets at the top and bottom, and a relief valve II is provided at the top. The top inlet and outlet are connected to the interior of the fibrinolysis mechanism through the pipeline III, and an adjustable speed roller pump head is installed on the pipeline III. The bottom inlet and outlet is provided with a pipeline V, and the outer end of the pipeline V extends out of the side wall of the temperature control fixing mechanism and is installed with a valve V.

[0011] Furthermore, valves I and valves II are installed on the outer walls of pipeline I and pipeline II respectively.

[0012] Furthermore, valves III and valves IV are installed on the outer walls of the pipeline III and the pipeline IV respectively.

[0013] The utility model has the following beneficial effects:

[0014] 1. The utility model provides a blood or plasma protein concentration stabilizing device for screening coefficient test, the main purpose of which is to separate fibrin solids in bovine blood or plasma, realize in vitro real-time fibrinolysis, prevent fibrin solids from clogging pipelines, filters or concentrators, and maintain the protein concentration in the blood circulation loop required for the screening coefficient test of hemodialyzer, hemodiafilter, hemofilter and hemoconcentrator stable at 60g / L±5g / L.

[0015] 2. The present invention can effectively realize the fibrinolysis of blood and the separation of solids through the combination of the fibrinolytic mechanism and the solid separation component, which is very important for subsequent experimental analysis.

[0016] 3. The utility model can ensure that blood or plasma is processed in a stable temperature environment through the temperature control module and the electric heating module inside the temperature control fixing mechanism, which is very important for maintaining the stability and activity of the protein.

[0017] 4. The utility model can prevent blood or plasma precipitation and stratification through the screw-type stirring component inside the blood storage mechanism, thereby ensuring the accuracy of the test results.

[0018] 5. The utility model allows users to flexibly adjust the flow speed and direction of blood or plasma to meet different test requirements through multiple valves (such as valve I, valve II, valve III, valve IV and valve V) on the pipeline and an adjustable speed roller pump head.

[0019] 6. The design of the device of the utility model takes good sealing into consideration, such as the setting of the air relief valve I and the air relief valve II, which can ensure that no safety problems will occur during operation due to excessively high or low pressure.

[0020] 7. The circular openable and closable operating window of the housing of the temperature control fixing mechanism of the utility model allows the user to conveniently observe the internal conditions and perform necessary maintenance and operations. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the technical solutions of the implementation methods of the present application, the drawings required for use in the implementation methods will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0022] Figure 1 It is a schematic diagram of a blood or plasma protein concentration stabilization device for screening coefficient test provided in an embodiment of the present application;

[0023] Figure 2 A front view schematic diagram of a blood or plasma protein concentration stabilization device for a screening coefficient test provided in an embodiment of the present application.

[0024] In the figure: 1- pipeline I; 2- pipeline II; 3- valve II; 4- air release valve I; 5- fibrinolysis mechanism; 6- solid separation component; 7- operation window; 8- temperature control fixing mechanism; 9- pipeline IV; 10- valve IV; 11- air release valve II; 12- valve V; 13- pipeline V; 14- temperature control module; 15- electric heating module; 16- baffle; 17- holder; 18- screw stirring component; 19- blood storage mechanism; 20- screw stirring component power measurement; 21- adjustable speed roller pump head; 22- valve III; 23- pipeline III; 24- injection port; 25- valve I. DETAILED DESCRIPTION

[0025] The technical solutions in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all of the embodiments.

[0026] Example:

[0027] See also Figure 1 , Figure 2 A blood or plasma protein concentration stabilizing device for screening coefficient test, comprising a fibrinolytic mechanism 5 provided at the bottom of a pipeline Ⅰ1, the fibrinolytic mechanism 5 is installed inside a temperature control fixing mechanism 8, a blood storage mechanism 19 is also provided inside the temperature control fixing mechanism 8, the fibrinolytic mechanism 5 and the blood storage mechanism 19 are connected by a pipeline Ⅳ9 and a pipeline Ⅲ23, both ends of the pipeline Ⅳ9 are fixedly connected to the side wall of the pipeline Ⅲ23, an adjustable speed rolling pump head 21 is installed on the pipeline Ⅲ23, a solid separation component 6 is sealed and connected to the top of the fibrinolytic mechanism 5, and a pipeline Ⅱ2 is also provided at the connection, and a vent valve Ⅰ4 and an injection port 24 are installed, an operating window 7 is provided on the outer wall of the temperature control fixing mechanism 8, a temperature control module 14 and an electric heating module 15 are installed on the inner bottom, and a baffle 16 is welded on the inner wall, and a side of the inner wall of the blood storage mechanism 19 is provided Fixer 17, and fixedly connected with pipeline III 23, a screw-type stirring component power measurement 20 and a vent valve II 11 are installed on the top of the blood storage mechanism 19, a screw-type stirring component 18 is installed on the inner top, and a pipeline V13 is provided on the outer wall, a valve V12 is installed on the pipeline V13, and valves I25 and valve II3 are installed on the outer walls of pipeline I1 and pipeline II2 respectively, and valves III22 and valve IV10 are installed on the outer walls of pipeline III23 and pipeline IV9 respectively; this design solves the problems in the prior art of realizing real-time fibrinolysis in vitro, preventing fibrin solids from clogging pipelines, filters or concentrators, and maintaining the protein concentration in the blood circulation circuit required for the screening coefficient test of hemodialyzers, hemodiafiltration devices, hemofilters and hemoconcentrators stable at 60g / L±5g / L.

[0028] Among them, the outer wall of the blood storage mechanism 19 is a plastic cylinder; a fixer 17 is provided on one side of the inner wall, which is used to fix the pipeline III inside the blood storage mechanism 19; the top center oil seal of the blood storage mechanism 19 fixes the screw stirring shaft, and the screw stirring component 18 is inside the blood storage mechanism 19; an appropriate gap is left between the outer edge of the screw stirring component 18 and the inner wall of the blood storage mechanism 19; an appropriate gap is left between the bottom edge of the screw stirring component 18 and the bottom plane of the blood storage mechanism 19.

[0029] Among them, the blood storage mechanism 19 is used to store and mix the blood or plasma after filtering the solids and the blood or plasma after fibrinolysis. The top and bottom of the blood storage mechanism 19 are provided with inlets and outlets. The top is provided with a relief valve Ⅱ11, and the inlet and outlet pipelines 13 are provided with an adjustable speed limiting valve 12, which can adjust the blood or plasma flow in and out speed at any time; the top inlet and outlet of the blood storage mechanism 19 are respectively connected to the fibrinolysis mechanism 5 and the adjustable speed roller pump head 21 through the pipeline 23, and the bottom inlet and outlet of the blood storage mechanism 19 is connected to the blood dynamic device in the blood circulation circuit through the pipeline 13.

[0030] Among them, the fibrinolytic mechanism 5 is an action unit for the solid matter in the blood or plasma to react with heparin to produce a fibrinolytic reaction. The fibrinolytic mechanism 5 includes a container-shaped outer shell, and a solid separation component 6 is arranged inside, which can filter the fibrin in the blood or plasma in real time; the fibrinolytic mechanism 5 is provided with inlets and outlets at the top and bottom, and a relief valve Ⅰ4 is arranged at the top, and the inlet and outlet pipelines are provided with an adjustable speed limiting valve, which can adjust the blood or plasma flow in and out speed at any time; the fibrinolytic mechanism 5 is provided with an injection port 24 at the top, which can quantitatively inject heparin to start the fibrinolytic reaction; the inlet and outlet at the top of the fibrinolytic mechanism 5 is connected to the blood circulation circuit through a pipeline, and the inlet and outlet at the bottom of the fibrinolytic mechanism 5 are respectively connected to the blood storage mechanism 19 and the adjustable speed roller pump head 21 through a pipeline 23.

[0031] Among them, the solid separation component 6 in the fibrinolysis mechanism 5 is a narrow plastic component on a conical cylinder, the upper part is sealed with the inner wall of the fibrinolysis mechanism 5, and the bottom is sealed with a filter screen with a fixed aperture of less than 0.05mm. The horizontal section of the filter screen should be located in the longitudinal middle of the inner wall of the fibrinolysis mechanism 5.

[0032] Among them, one of the connection forms between the blood storage mechanism 19 and the fibrinolytic mechanism 5 is a pipeline with an adjustable speed-limiting valve, which provides a path for blood or plasma to be transported from the fibrinolytic mechanism 5 to the blood storage mechanism 19 when no fibrinolytic reaction is required.

[0033] Among them, the second connection form between the blood storage mechanism 19 and the fibrinolysis mechanism 5 is an adjustable speed rolling pump head 21. When the fibrinolysis reaction is started, a passage is provided for the blood or plasma to be transported from the blood storage mechanism 19 to the fibrinolysis mechanism 5, forming a blood or plasma flow in the opposite direction of the blood or plasma circulation passage, which is beneficial for the fibrinolytic protein attached to the solid separation component 6 to fully react with heparin and elute and dissolve; changing the rolling direction can accelerate the transportation of blood or plasma from the fibrinolysis mechanism 5 to the blood storage mechanism 19, and provide a power source for mixing the blood or plasma after filtering the solids and the blood or plasma after fibrinolysis.

[0034] Among them, the temperature control fixing mechanism 8 has an appearance of a table-top rectangular configuration, the bottom plate and the back plate are made of stainless steel, and the other facades and the top shell are made of transparent polymer material; a circular openable and closable operating window 7 is reserved on the front plate of the shell, and the size of the operating window is suitable for one-handed adjustment of valve III 22 and valve IV 10, switching the rolling direction of the pump head and opening and closing the power of the screw stirring component 18; the top plate of the shell has pipe I1 and pipe II 2 hole grooves; the side plate of the shell has pipe V 13 hole grooves.

[0035] Among them, an electric heating module 15 and a temperature control module 14 are installed above the bottom plate of the temperature control fixing mechanism 8 to achieve a constant temperature inside the fixing device at 37±3°C or 65±3°C; an insulating baffle 16 is set in the middle cross section, and an appropriate distance is left between the baffle 16 and the lower electric heating module 15 and the temperature control module 14, and air channels are left around the baffle 16 to achieve heat exchange and uniform temperature of the air inside the temperature control fixing mechanism 8; above the insulating baffle 16, an acrylic ring base is fixed by screws, and the inner diameter of the base is adapted to the outer diameter of the bottom of the blood storage mechanism 19, which is used to fix the blood storage mechanism 19 in the horizontal direction, and a groove is set at the corresponding position of the base to adapt to the pipeline V13.

[0036] The temperature control and fixing mechanism 8 is provided with stainless steel fixing brackets at the bottom, middle and upper part of the fibrinolysis mechanism 5, and the brackets are fixed to the corresponding positions of the back plate with screws.

[0037] The temperature control fixing mechanism 8 fixes the adjustable speed roller pump head 21 to the corresponding position of the back plate with screws, and is easy to install and disassemble.

[0038] Among them, the blood storage mechanism 19, the fibrinolytic mechanism 5, the inner and outer walls of the pipeline and the solid separation component 6 are all resistant to acid, alkali and heat treatments, ensuring that the device can be cleaned and disinfected after use and reused.

[0039] Among them, when blood or plasma is perfused for the first time, valve I 25, valve III 22, and valve IV 10 are opened, valve II 3 and valve V 12 are closed, and the adjustable speed roller pump head 21 is opened in the direction of the fibrinolysis mechanism 5 → blood storage mechanism 19, and adjusted to medium speed until all the blood or plasma enters the blood storage mechanism 19. At this time, all the fibrin solids in the initial blood or plasma are attached to the filter screen part of the solid separation component 6 in the fibrinolysis mechanism 5; the adjustable speed roller pump head 21, valve I 25, valve III 22, valve IV, and valve V 12 are closed.

[0040] Among them, according to the thickness of the solid fibrin adhesion at the filter screen, low molecular weight heparin sodium is injected at the injection port 24, valve III 22 is opened, and the adjustable speed roller pump head 21 is turned on in the direction of the blood storage mechanism 19 → the fibrinolysis mechanism 5, and adjusted to high speed. At this time, the filtered blood or plasma flows rapidly from the blood storage mechanism 19 through the pipeline to the solid separation component 6 in the fibrinolysis mechanism 5 and immerses the filter screen for at least 3 cm, and the valve III 22 and the adjustable speed roller pump head 21 are closed; while dissolving the low molecular weight heparin sodium, a local anti-gravity direction force is formed at the solid separation component 6; under the action of the force, the fibrin at the filter screen is eluted and dispersed, increasing the contact area with the low molecular weight heparin sodium, and achieving rapid dissolution; the action time is 10 minutes.

[0041] Among them, valve III 22 and the screw stirring component 18 are opened, and the adjustable speed roller pump head 21 is opened in the direction of the fibrinolysis mechanism 5 → the blood storage mechanism 19, and adjusted to a high speed until all the blood or plasma after the fibrinolysis reaction flows rapidly from the fibrinolysis mechanism 5 to the blood storage mechanism 19 through the pipeline, and the valve III 22 and the adjustable speed roller pump head 21 are closed; under the uniform rotation of the screw stirring component 18, the blood or plasma after fibrinolysis is evenly mixed with the blood or plasma after the first filtration of fibrin.

[0042] Among them, after the above-mentioned technical scheme, observe the residual fibrin in the solid separation component 6. If there is still residual, open the adjustable speed roller pump head 21 in the direction of the blood storage mechanism 19 → the fibrinolysis mechanism 5, adjust it to high speed, and the blood or plasma flows rapidly from the blood storage mechanism 19 through the pipeline to the solid separation component 6 in the fibrinolysis mechanism 5 and immerses the filter screen for at least 3 cm. Close the valve III 22 and the adjustable speed roller pump head 21, and the action time is 10 minutes; open the valve III 22 and the screw stirring component 18, open the adjustable speed roller pump head 21 in the direction of the fibrinolysis mechanism 5 → the blood storage mechanism 19, adjust it to high speed, until all the blood or plasma after the fibrinolysis reaction flows rapidly from the fibrinolysis mechanism 5 through the pipeline to the blood storage mechanism 19, close the valve III 22 and the adjustable speed roller pump head 21; under the uniform rotation of the screw stirring component 18, the fibrinolyzed blood or plasma is evenly mixed with the blood or plasma after the first filtration of fibrin.

[0043] Among them, valve II3, valve IV10, and valve V12 are opened to start the screening coefficient test. The device constitutes a part of the blood circulation circuit.

[0044] Among them, the screening coefficient test time exceeds 30 minutes, open valve III 22 and roller pump head 21 in the direction of fibrinolysis mechanism 5 → blood storage mechanism 19, adjust to low speed until the blood or plasma level in the fibrinolysis mechanism 5 is lower than the filter screen of the solid separation component 6, observe and monitor the fibrin fixation of the filter screen.

[0045] Among them, when it is observed and monitored during the screening coefficient test that the fibrin fixation on the filter screen part requires a fibrinolytic reaction, an appropriate amount of low molecular weight heparin sodium is injected at the injection port 24, and the direction of the roller pump head is adjusted from the blood storage mechanism 19 to the fibrinolytic mechanism 5, and the speed is adjusted to a low speed until the blood or plasma liquid level in the fibrinolytic mechanism 5 submerges the filter screen, and a local anti-gravity force is formed at the solid separation component 6 to form a vortex with the blood or plasma flow in the gravity direction of the blood circulation flow circuit in the pipeline II 2; the fibrin at the filter screen is eluted and dispersed under the action of the vortex, thereby increasing the contact area with the low molecular weight heparin sodium and achieving rapid disintegration.

[0046] Among them, after observing and monitoring the disintegration of part of the fibrin on the filter screen during the screening coefficient test, the direction of the roller pump head is adjusted from the fibrinolysis mechanism 5 to the blood storage mechanism 19, and adjusted to a high speed until the blood or plasma after the fibrinolysis reaction flows rapidly from the fibrinolysis mechanism 5 to the blood storage mechanism 19 through the pipeline, and the adjustable speed roller pump head 21 is adjusted to a low speed. Under the combined action of the blood or plasma fluid force and the axial liquid flow and lateral shear force generated by the uniform rotation of the screw stirring component 18, the fibrinolyzed blood or plasma and the blood or plasma in the blood storage mechanism 19 are quickly and evenly mixed.

[0047] Among them, the blood storage mechanism 19 is designed with a screw stirring component 18 made of PTFE material on the surface, which has low surface tension, large axial liquid flow, and produces a large liquid circulation volume, effectively avoiding local circulation in the blood storage mechanism 19 and achieving rapid mixing of high-viscosity liquids such as blood or plasma.

[0048] Among them, the top surface of the central axis of the blood storage mechanism 19 is designed to be attached with a PTFE material shaft sealing component to achieve the wear resistance and sealing properties of the shaft.

[0049] The bottom end of the pipeline III 23 is designed to be at the bottom of the blood storage mechanism 19 to avoid empty suction, reduce the generation of bubbles, hemolysis and other adverse events, and facilitate the full mixing of the fibrinolyzed blood or plasma with the filtered blood or plasma.

[0050] Among them, one of the connection forms between the blood storage mechanism 19 and the fibrinolytic mechanism 5 is an energy-saving and consumption-reducing design, which serves as an auxiliary passage for the filtered blood or plasma to flow from the blood storage mechanism 19 to the fibrinolytic mechanism 5.

[0051] Among them, the second connection form between the blood storage mechanism 19 and the fibrinolytic mechanism 5 is a buffer path between the main power source of the blood circulation circuit and the auxiliary power source of the utility model, which serves as the main flow channel of blood or plasma when the main power source and the auxiliary power source of the utility model are in opposite directions.

[0052] Among them, after the screening coefficient test is completed, open valve Ⅰ25, valve Ⅲ22, and valve Ⅴ12; pipeline Ⅰ1 is connected to the acid / alkaline cleaning solution, and pipeline Ⅴ13 is connected to the waste liquid storage tank; open the adjustable speed roller pump head direction 21, the direction is fibrinolytic mechanism 5→blood storage mechanism 19, adjust to low speed, control the flow rate of valve Ⅴ12, and realize that the acid / alkaline cleaning solution flows through and fills the fibrinolytic device, pipeline Ⅲ23 and blood storage device in turn, and is discharged to the waste liquid storage tank; the cleaning time can be adjusted as needed; cancel pipeline Ⅰ1 connecting the acid / alkaline cleaning solution, until all the acid / alkaline cleaning solution is discharged to the waste liquid storage tank.

[0053] Among them, after the screening coefficient test is completed, open valve Ⅰ25, valve Ⅳ10, and valve Ⅴ12; pipeline Ⅰ1 is connected to the acid / alkaline cleaning solution, and pipeline Ⅴ13 is connected to the waste liquid storage tank; turn on the main power source of the blood circulation loop, adjust it to a low speed, and control the flow rate of valve Ⅴ112 to allow the acid / alkaline cleaning solution to flow through and fill the fibrinolytic device, pipeline Ⅳ9 and the blood storage device in turn, and be discharged to the waste liquid storage tank; the cleaning time can be adjusted as needed; cancel pipeline Ⅰ1 connected to the acid / alkaline cleaning solution, until all the acid / alkaline cleaning solution is discharged to the waste liquid storage tank.

[0054] During the test, the temperature control fixing mechanism 8 is adjusted to achieve a constant temperature of 37±3°C, so that the fibrinolytic mechanism 5, the blood storage mechanism 19 and the blood or plasma in the pipeline are maintained in the same temperature environment as the human body, so that the test results are accurate and reliable.

[0055] After the acid / alkaline cleaning is completed, the temperature control fixing mechanism 8 is adjusted to achieve a constant temperature of 65±3° C., thereby achieving drying and disinfection of the fibrinolytic mechanism 5 , the blood storage mechanism 19 and the pipeline.

[0056] It should be noted that the temperature control module 14 and the electric heating module 15 are both products in the prior art. The temperature control module 14 is the temperature control module in the prior art, and the electric heating module 15 is the electric heater in the prior art. The specific model specifications of the temperature control module 14 and the electric heating module 15 need to be selected and determined based on the actual specifications of the device. The specific selection calculation method adopts the existing technology in this field, so it will not be described in detail.

[0057] The power supply and principle of the temperature control module 14 and the electric heating module 15 are clear to those skilled in the art and will not be described in detail here.

[0058] It is obvious to those skilled in the art that the present application is not limited to the details of the exemplary embodiments described above, and that the present application can be implemented in other specific forms without departing from the spirit or essential features of the present application. Therefore, the embodiments should be regarded as exemplary and non-limiting in all respects, and the scope of the present application is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present application. Any reference numeral in a claim should not be regarded as limiting the claim to which it relates.

Claims

1. A blood or plasma protein concentration stabilization device for screening coefficient test, comprising a pipeline I (1), characterized in that: A fibrinolytic mechanism (5) is provided at the bottom of the pipeline I (1), and the fibrinolytic mechanism (5) is installed inside the temperature control fixing mechanism (8). A blood storage mechanism (19) is also provided inside the temperature control fixing mechanism (8). The fibrinolytic mechanism (5) and the blood storage mechanism (19) are connected via a pipeline IV (9) and a pipeline III (23), and both ends of the pipeline IV (9) are fixedly connected to the side wall of the pipeline III (23). A temperature control module (14) and an electric heating module (15) are installed at the bottom of the temperature control fixing mechanism (8).

2. A blood or plasma protein concentration stabilization device for screening coefficient test according to claim 1, characterized in that: A solid separation component (6) is provided inside the fibrinolytic mechanism (5), and the top of the solid separation component (6) is sealed and connected to the top of the fibrinolytic mechanism (5) in a concentric circle form. The pipeline I (1) and the pipeline II (2) are fixedly installed at the sealed connection between the fibrinolytic mechanism (5) and the solid separation component (6), the bottom end of the pipeline I (1) is close to the bottom of the solid separation component (6), and the bottom end of the pipeline II (2) is higher than the bottom end of the pipeline I (1). A deflation valve I (4) is provided on one side of the top of the fibrinolytic mechanism (5), and an injection port (24) is provided on the other side.

3. A blood or plasma protein concentration stabilization device for screening coefficient test according to claim 2, characterized in that: The outer shell of the temperature control fixing mechanism (8) is provided with a circular openable and closable operating window (7); the tops of the temperature control module (14) and the electric heating module (15) are provided with a baffle (16); the side wall of the baffle (16) is fixedly connected to the inner wall of the temperature control fixing mechanism (8); and the surface is fixedly connected to the bottom of the blood storage mechanism (19).

4. A blood or plasma protein concentration stabilization device for screening coefficient test according to claim 3, characterized in that: A fixer (17) is provided on one side of the inner wall of the blood storage mechanism (19), and the fixer (17) is fixedly connected to the bottom outer wall of the pipeline III (23). A screw stirring component (18) is installed at the top of the blood storage mechanism (19), and a screw stirring component power measurement (20) is installed at the top. The screw stirring component (18) and the screw stirring component power measurement (20) are connected to each other in a transmission manner.

5. A blood or plasma protein concentration stabilization device for screening coefficient test according to claim 4, characterized in that: The blood storage mechanism (19) is provided with an inlet and outlet at the top and the bottom, and a relief valve II (11) is provided at the top. The top inlet and outlet are connected to the inside of the fibrinolysis mechanism (5) through the pipeline III (23), and an adjustable speed roller pump head (21) is installed on the pipeline III (23). The bottom inlet and outlet is provided with a pipeline V (13), and the outer end of the pipeline V (13) extends out of the side wall of the temperature control fixing mechanism (8) and is installed with a valve V (12).

6. A blood or plasma protein concentration stabilization device for screening coefficient test according to claim 5, characterized in that: The outer walls of the pipeline I (1) and the pipeline II (2) are respectively provided with a valve I (25) and a valve II (3).

7. A blood or plasma protein concentration stabilizing device for screening coefficient test according to claim 6, characterized in that: The outer walls of the pipeline III (23) and the pipeline IV (9) are respectively provided with a valve III (22) and a valve IV (10).

Images